<?xml version="1.0" encoding="UTF-8"?>
<p>Most patients were male (
 <italic>n</italic> = 43; 60.6%) and white (
 <italic>n</italic> = 60; 84.5%), with a median age of 64.0 (range 27‐75) years. The majority of patients had Eastern Cooperative Oncology Group performance status 1 (
 <italic>n</italic> = 44; 62.0%) and good/intermediate cytogenetic risk (ie, favorable, intermediate‐I, or intermediate‐II risk; 
 <italic>n</italic> = 50; 70.4%) (Supporting Information 
 <xref rid="ajh25238-supitem-0001" ref-type="supplementary-material">Table S1</xref>). Seven (9.9%) patients received prior hypomethylating agents (decitabine or azacitidine).
</p>
